Trial Profile
A Phase I Study of Combination Anticancer Therapy of Paclitaxel and RAD001 for Relapsed or Refractory Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Nov 2013
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Paclitaxel
- Indications Small cell lung cancer
- Focus Adverse reactions
- 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jul 2011 Planned end date changed from 1 May 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 06 Mar 2010 New trial record